Immunovant, Inc.
IMVTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeImmunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. With a market capitalization of $6.35B, it sits in mid-cap territory. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Market Cap
$6.35B
Beta
0.70
P/E (TTM)
—
P/E (Fwd)
-12.69
EPS (TTM)
$-2.77
EPS (Fwd)
$-2.44
ROE
-64.8%
ROA
-38.4%
Cash
$902.1M
Total Debt
$72,000
Free CF
-$234.3M
52W Change
101.6%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $902.1M in cash comfortably exceeding the $72K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$234.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -64.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, IMVT has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Immunovant, Inc. and its sector.